Revvity (NYSE:RVTY) Releases Quarterly Earnings Results, Beats Expectations By $0.20 EPS

Revvity (NYSE:RVTY) posted its earnings results on Tuesday. The company reported $1.41 earnings per share for the quarter, topping analysts’ consensus estimates of $1.21 by $0.20, Zacks reports. The firm had revenue of $711.00 million for the quarter, compared to the consensus estimate of $702.96 million. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The business’s quarterly revenue was down 1.3% on a year-over-year basis. During the same period in the previous year, the firm posted $1.18 EPS. Revvity updated its FY 2026 guidance to 5.300-5.400 EPS.

Here are the key takeaways from Revvity’s conference call:

• Revvity reported Q2 revenue of $711 million, 3% pro forma organic growth, and adjusted EPS of $1.41, exceeding expectations. Performance benefited from stronger operations, favorable tax timing, and $16 million in tariff refunds.
• The company raised its 2026 outlook to 4%–5% organic growth, approximately 28.7% adjusted operating margin, and adjusted EPS of $5.30–$5.40. Management said the guidance assumes continued improvement in pharma and biotech spending but no further acceleration beyond current trends.
• Diagnostics remained a major strength, growing 11% organically, with reproductive health up in the mid-teens and Immunodiagnostics outside China accelerating to high-single-digit growth. Newborn screening and the Genomics England sequencing contract continued to support results.
• AI-related demand is driving increased orders for high-content screening instruments, particularly the Opera Phenix OptIQ, with double-digit growth and backlog exceeding near-term production capacity. Management expects subsequent reagent pull-through as customers expand their lab-in-the-loop workflows.
• Signals software revenue declined approximately 20% year over year because of contract timing and difficult comparisons, although annualized portfolio value and ARR continued to grow strongly. Management expects a return to double-digit organic growth in the second half, making the recovery dependent on renewals and adoption of new AI-enabled offerings.

Revvity Stock Up 3.4%

RVTY stock opened at $115.19 on Thursday. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.80 and a quick ratio of 1.41. The firm has a market cap of $12.85 billion, a price-to-earnings ratio of 54.85, a PEG ratio of 2.15 and a beta of 1.07. Revvity has a 1-year low of $81.22 and a 1-year high of $118.30. The firm has a fifty day moving average price of $107.53 and a two-hundred day moving average price of $99.91.

Revvity Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Friday, October 23rd will be paid a dividend of $0.07 per share. The ex-dividend date is Friday, October 23rd. This represents a $0.28 annualized dividend and a yield of 0.2%. Revvity’s dividend payout ratio (DPR) is 13.40%.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Stifel Nicolaus decreased their target price on Revvity from $110.00 to $100.00 and set a “hold” rating for the company in a research report on Wednesday, May 6th. Barclays upped their price target on Revvity from $95.00 to $105.00 and gave the company an “equal weight” rating in a research report on Thursday, May 7th. Sanford C. Bernstein assumed coverage on shares of Revvity in a research note on Friday, June 26th. They set a “market perform” rating and a $115.00 target price on the stock. Robert W. Baird set a $117.00 price target on Revvity in a research note on Wednesday, May 6th. Finally, Zacks Research upgraded Revvity from a “strong sell” rating to a “hold” rating in a research note on Tuesday. Three research analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company. According to MarketBeat.com, Revvity presently has a consensus rating of “Hold” and an average target price of $108.36.

Hedge Funds Weigh In On Revvity

Several hedge funds have recently made changes to their positions in RVTY. CYBER HORNET ETFs LLC purchased a new position in Revvity during the 2nd quarter worth approximately $32,000. MUFG Securities EMEA plc acquired a new position in shares of Revvity in the 2nd quarter valued at about $34,000. Headlands Technologies LLC purchased a new position in Revvity during the second quarter valued at approximately $49,000. Los Angeles Capital Management LLC purchased a new position in shares of Revvity during the 4th quarter valued at $51,000. Finally, Aster Capital Management DIFC Ltd acquired a new stake in Revvity during the fourth quarter valued at $72,000. Institutional investors and hedge funds own 86.65% of the company’s stock.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.